Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-103 for psychosis in Parkinson's disease
2007-002906-23Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and Schizophrenia Spectrum Disorders (SSD) comparing Pimavanserin with Placebo (2 arms). Started Aug 2007; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2007-002906-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002906-23.